2don MSN
Bio-Techne expects Q4 organic growth approximately flat while targeting ~100 bps margin expansion
Q3 fiscal 2026 Management View "The Bio-Techne team continued to execute with discipline in a dynamic and uneven end market environment" and said results were supported by "sustained strength from our ...
Bio-Techne (NASDAQ:TECH) reported fiscal third-quarter 2026 results marked by uneven end-market conditions, with strong ...
While each product featured is independently selected by our editors, we may include paid promotion. If you buy something through our links, we may earn commission. Read more about our Product Review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results